Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through

Wen-Yu Huang1, Pei-Ming Yang, Yu-Fan Chang

  • 1Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 10018, Taiwan.

Biochemical Pharmacology
|December 1, 2010
PubMed

Insights

Methotrexate (MTX) effectively combats non-small cell lung cancer (NSCLC) by triggering programmed cell death (apoptosis) and restoring E-cadherin expression. This anticancer action is mediated through p53 activation and inhibition of HDAC/EZH2 pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Methotrexate (MTX) is a dihydrofolate reductase (DHFR) inhibitor utilized in cancer chemotherapy.
  • Non-small cell lung cancer (NSCLC) remains a significant global health challenge.
  • Understanding the precise molecular mechanisms of MTX in NSCLC is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To elucidate the anti-tumor mechanisms of Methotrexate (MTX) in non-small cell lung cancer (NSCLC) A549 cells.
  • To investigate the role of p53 and E-cadherin in MTX-induced anti-cancer effects.
  • To explore the impact of MTX on epigenetic regulators like HDAC and EZH2.

Main Methods:

  • In vitro cell growth inhibition assays and apoptosis induction studies.
  • Animal xenograft models to assess in vivo tumor formation.
  • RNase protection assay (RPA) and RT-PCR to analyze gene expression.
  • Western blotting to evaluate protein phosphorylation and acetylation.

Main Results:

  • MTX inhibited NSCLC A549 cell growth and tumor formation in vivo.
  • MTX induced apoptosis via upregulation of p53 target genes (DR5, p21, Puma, Noxa).
  • MTX promoted p53 stability and expression through phosphorylation and acetylation.
  • MTX increased E-cadherin expression by inhibiting HDAC activity and downregulating EZH2.

Conclusions:

  • MTX exhibits anti-cancer effects in NSCLC through p53-dependent apoptosis induction.
  • MTX restores E-cadherin expression by modulating HDAC/EZH2 pathways.
  • The findings provide insights into MTX's therapeutic potential and mechanisms in NSCLC treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...